cas 253870-02-9|| where to buy 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

製品名:5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

IUPAC Name:5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

包装単位	有効在庫	価格（USD）
CM100701-100g	in stock	ƈĲƥ
CM100701-500g	in stock	ƥǪŗ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 253870-02-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:253870-02-9; 分子式:C8H9NO3; 融点:-; SMILESコード:O=C(C1=C(C)NC(C=O)=C1C)O; 密度:

: カタログ番号:CM100701; 分子量:167.16; 沸点:; MDL番号:MFCD06202342; 保管方法:Store at 2-8°C.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.; Pyrrole,Where to Buy Pyrroles-Chemenu; Pyrrole,Where to Buy Pyrroles; Pyrrole is a heterocyclic, aromatic, organic compound, a five-membered ring with the formula C 4H 4NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole.

: Vorolanib; EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.